Search

EHA-ISHBT Hematology Tutorial on Hematological Disorders

Dates: February 28-29, 2020
Location: Chandigarh, India
Chairs: N Varma, P Malhotra, J Gribben

Organized by: European Hematology Association (EHA) & Indian Society of Hematology and Blood Transfusion (ISHBT)

EHA will join ISHBT for a fourth time to organize the EHA-ISHBT Hematology Tutorial, this time in Chandigargh,…

Read more

Faculty Information

We are honored that you have agreed to be part of the faculty for the EHA-ISHBT Hematology Tutorial, to be held on March 1-3, 2024 in Hyderabad, India.

Read more

Position of EHA on the Harmonization of Training and Education in Europe

 

The challenge
Education and training are largely national competencies.

Read more

Revising the ICH Guidelines on Clinical Trials

The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.

Read more

1st European EHA Sickle Cell Conference

EHA is teaming up with the Annual Scientific Conference on Sickle Cell and Thalassaemia, 2020 and the British Society of Haematology (BSH) to co-organize this first European Sickle Cell Conference; and also as a result of COVID-19 offer it as…

Read more

HARMONY: Better care of patients with hematologic malignancies kicked off!

“Combining data available from clinical trials as well as real world patients allows us to do more advanced analyses on possible treatment options that could be effective for individual patient or categories of patients”, said Jesús María Hernandez Rivas, Project…

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more